紫龙金片对肺癌患者术后免疫功能的调节作用

Effect of Zilongjin Tablets on immune function of patients with lung cancer after operation

目的从体液免疫及细胞免疫角度探讨紫龙金片对肺癌患者术后免疫功能的调节作用。方法将60例肺癌术后患者按数字随机表分为2组,对照组及治疗组各30例。对照组术后给予常规支持治疗,治疗组在术后常规支持治疗基础上第3天起口服紫龙金片(每次4片,3次/d)治疗,比较两组患者的免疫球蛋白(IgA、IgG、IgM)、T细胞亚群(CD3^+、CD4^+、CD8^+、CD4^+/CD8^+)及NK细胞等指标。结果术后第2天两组IgA、IgG、IgM、CD3^+、CD4^+、CD4^+/CD8^+与术前比较均下降,差异显著(P<0.05),CD8^+差异不显著(P>0.05);术后第14天对照组及治疗组IgA、IgG、IgM、CD3^+、CD4^+、CD4^+/CD8^+、NK与术后第2天比较均有上升,对照组NK差异显著(P<0.05),治疗组IgA、IgG、IgM、CD3^+、CD4^+、CD4^+/CD8^+差异显著(P<0.05);术后第14天治疗组IgA、IgG、CD4^+、CD4^+/CD8^+、NK与对照组比较,均显著升高(P<0.05)。结论肺癌患者手术后早期存在免疫功能抑制状态,紫龙金片可以改善肺癌患者术后体液免疫和细胞免疫功能,促进机体免疫功能恢复,增强机体抗肿瘤能力。

Objective To explore the regulatory effect of Zilongjin Tablet on immune function of postoperative patients with lung cancer from humoral immunity and cellular immunity, and to seek an effective method for comprehensive treatment of lung cancer. Methods Sixty patients with lung cancer after operation were divided into two groups according to the digital random table, 30 in the control group and 30 in the treatment group. The control group was given routine supportive treatment after operation. The treatment group was given Zilongjin Tablets (4 tablets, 3 times/d) with routine supportive treatment on day 3 after operation. The indexes of immunoglobulin (IgA, IgG, IgM), T lymphocyte subsets (CD3^+, CD4^+, CD8^+, CD4^+/CD8^+), and NK cells were compared between the two groups. Results On day 2 after operation, IgA, IgG, IgM, CD3^+, CD4^+, CD4^+/CD8^+ in the two groups decreased compared with those before operation, and the difference was statistically significant (P < 0.05), but there was no significant difference in CD8^+(P > 0.05). On day 14 after operation, the levels of IgA, IgG, IgM, CD3^+, CD4^+, CD4^+/CD8^+, NK in the two groups increased, the NK of the control group and the IgA, IgG, IgM, CD3^+, CD4^+, CD4^+/CD8^+ of the treatment group were significant differences compared with the 2nd day after operation (P < 0.05). Moreover, there were significant differences in IgA, IgG, CD4^+, CD4^+/CD8^+, NK between the two groups on day 14 after operation (P < 0.05). Conclusion Patients with lung cancer have immunosuppressive status in the early postoperative period. Zilongjin Tablets can improve the postoperative humoral immunity and cellular immunity of patients with lung cancer, promote the recovery of immune function and enhance their anti-tumor ability.